NATCAPSUQ
Natural Capsules Limited (NATCAPSUQ) Stock Analysis
Natural Capsules Limited is an Indian pharmaceutical empty capsules manufacturer supplying gelatin and HPMC capsules to drug makers globally. It operates high-speed capsule lines with export certifications. Volume growth follows generic pharma production worldwide. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹160.00
-1.33% 1W | -32.40% 52W
Market Cap
167 CR
P/E Ratio
–
52W High
₹244.9
52W Low
₹136.4
Div. Yield
0%
Beta
0
50 DMA
₹172.2
200 DMA
₹161.6
Profit Margin
-8.1%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 37.70 | 37.52 | 39.98 | 40.22 | 39.18 | 41.22 | 43.83 | 44.97 | 45.20 | 45.80 | 37.75 | 58.45 | 48.71 |
| Expenses | 31.74 | 32.40 | 35.26 | 36.11 | 34.81 | 36.72 | 39.56 | 40.58 | 44.88 | 46.69 | 40.07 | 57.12 | 47.59 |
| Operating Profit | 5.96 | 5.12 | 4.72 | 4.11 | 4.37 | 4.50 | 4.27 | 4.39 | 0.32 | -0.89 | -2.32 | 1.33 | 1.12 |
| OPM % | 15.81% | 13.65% | 11.81% | 10.22% | 11.15% | 10.92% | 9.74% | 9.76% | 0.71% | -1.94% | -6.15% | 2.28% | 2.30% |
| Other Income | 0.17 | 0.35 | 0.50 | 0.92 | 0.18 | 0.11 | 0.11 | 0.30 | 0.36 | 0.16 | 0.45 | 0.76 | 2.35 |
| Interest | 1.33 | 1.16 | 1.24 | 1.40 | 1.49 | 1.65 | 1.54 | 1.64 | 2.53 | 2.68 | 2.85 | 2.89 | 4.97 |
| Depreciation | 2.11 | 2.17 | 2.19 | 2.20 | 2.28 | 2.35 | 2.33 | 2.16 | 4.21 | 4.29 | 4.36 | 4.28 | 4.33 |
| Profit before tax | 2.69 | 2.14 | 1.79 | 1.43 | 0.78 | 0.61 | 0.51 | 0.89 | -6.06 | -7.70 | -9.08 | -5.08 | -5.83 |
| Tax % | 32.34% | 27.10% | 32.96% | 32.17% | 21.79% | 201.64% | 78.43% | 41.57% | -8.09% | -9.09% | -21.70% | -1.97% | -1.54% |
| Net Profit | 1.82 | 1.56 | 1.21 | 0.97 | 0.60 | -0.61 | 0.11 | 0.52 | -5.58 | -6.99 | -7.12 | -4.98 | -5.75 |
| EPS in Rs | 1.96 | 1.68 | 1.30 | 1.04 | 0.64 | -0.60 | 0.11 | 0.35 | -5.40 | -6.76 | -4.77 | -3.32 | -3.82 |
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 60 | 62 | 80 | 135 | 170 | 155 | 169 | 187 | 191 |
| Expenses | 49 | 55 | 56 | 68 | 110 | 135 | 135 | 151 | 188 | 191 |
| Operating Profit | 6 | 5 | 5 | 11 | 26 | 35 | 20 | 18 | -1 | -1 |
| OPM % | 10% | 8% | 9% | 14% | 19% | 21% | 13% | 10% | -0.5% | -0.4% |
| Other Income | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 4 |
| Interest | 0 | 1 | 1 | 1 | 2 | 4 | 5 | 7 | 12 | 13 |
| Depreciation | 4 | 3 | 4 | 4 | 5 | 7 | 9 | 9 | 17 | 17 |
| Profit before tax | 2 | 2 | 1 | 9 | 19 | 25 | 8 | 3 | -28 | -28 |
| Tax % | 34% | 7% | 38% | 24% | 28% | 26% | 31% | 78% | -12% | |
| Net Profit | 1 | 2 | 1 | 7 | 14 | 18 | 6 | 1 | -25 | -25 |
| EPS in Rs | 1.19 | 2.06 | 0.92 | 7.43 | 14.96 | 20.02 | 5.95 | 0.42 | -16.44 | -18.67 |
| Dividend Payout % | 56% | 32% | 43% | 9% | 5% | 5% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 3.0% | 19.0% | – |
Shareholding Pattern
Promoters51.26%
Public48.75%
Promoters51.26%
Public48.73%
Promoters51.26%
Public48.74%
Promoters51.04%
Public48.96%
Promoters50.92%
Public49.09%
Promoters56.57%
DIIs1.31%
Public42.13%
Promoters56.57%
DIIs1.31%
Public42.13%
Promoters51.21%
Public48.80%
Promoters51.04%
Public48.96%
Promoters50.92%
Public49.09%
NATCAPSUQ
Holdings Analysis
Key strengths & risk signals
46
Overall
29
Fundamental
64
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 32.4% in the last year.
WEAK POSITION! Current price (160.0) is below both moving averages.
LOWER HALF! Trading at 21.8% of 52W range - weakness visible.
Strengths (3)
BULLISH TREND! 50-day average (172.2) is above 200-day average (161.6) - positive signal.
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 36,016 vs down days: 14,814. Ratio: 2.43x
NEUTRAL! RSI at 41.5 - balanced momentum.
Fundamental & Technical Analysis
46Overall
29Fundamental
64Technical
Fundamental Breakdown
Growth Quality
7/30
Revenue CAGR: 3.6% (SLOW, 5/15). Profit CAGR: 0% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! -8.1% profit margin - thin profits.
PEG Valuation
0/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 42.13% public ownership - higher volatility risk.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (172.2) is above 200-day average (161.6) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (160.0) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
0/10
POOR YEAR! Stock declined 32.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 12 up days, 18 down days. Avg volume on up days: 36,016 vs down days: 14,814. Ratio: 2.43x
RSI
3/5
NEUTRAL! RSI at 41.5 - balanced momentum.
52W Range
2/5
LOWER HALF! Trading at 21.8% of 52W range - weakness visible.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -1.3% (1 week), -17.6% (1 month), 10.4% (3 months).
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
NATCAPSUQ
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-06-03 | Concall PDF | |
| Q2FY262025-11-19 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NATCAPSUQ | ₹160.00 | – | -8.1% | 3.6% | – | -32.4% | 46 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| BALPHARMA | ₹93.10 | 20.5 | 2.2% | 0.1% | 34.7% | +18.7% | 66 | CONSOLIDATING UP | +450.0% | -69.4% | +34.4% | +5.4% |
| MEDICO | ₹22.80 | 13.7 | 5.8% | 13.8% | 21.9% | -55.7% | 55 | BREAKDOWN | +38.9% | -57.6% | +81.2% | +22.2% |
| PAR | ₹117.10 | 11 | 13.3% | 11.0% | 1.0% | +21.6% | 66 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| NECLIFE | ₹10.10 | 28.9 | – | – | – | -24.9% | 46 | BREAKDOWN | -75.6% | -77.3% | – | – |
| BROOKS | ₹70.10 | 15.6 | 15.9% | 11.0% | – | -52.9% | 62 | BREAKOUT | -118.8% | -220.0% | -9.8% | +13.9% |
| BALAXI | ₹22.30 | 49.6 | 0.5% | -7.1% | -68.6% | -48.5% | 51 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| KREBSBIO | ₹56.00 | – | -55.9% | -23.1% | – | -16.8% | 47 | BREAKDOWN | -52.8% | +8.7% | +27.3% | +2.9% |
Data from TradeAlone · Updated daily
